- /
- Supported exchanges
- / US
- / OCS.NASDAQ
Oculis Holding AG Ordinary shares (OCS NASDAQ) stock market data APIs
Oculis Holding AG Ordinary shares Financial Data Overview
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases in Switzerland, Iceland, and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Oculis Holding AG Ordinary shares (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Oculis Holding AG Ordinary shares data using free add-ons & libraries
Get Oculis Holding AG Ordinary shares Fundamental Data
Oculis Holding AG Ordinary shares Fundamental data includes:
- Net Revenue: 791 K
- EBITDA: -77 789 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-11
- EPS/Forecast: -0.4116
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Oculis Holding AG Ordinary shares News
New
Pre-Market Earnings Report for November 18, 2025 : HD, PDD, MDT, BIDU, ESLT, AS, BZ, JHX, BRBR, ENR, WB, OCSL
The following companies are expected to report earnings prior to market open on 11/18/2025. Visit our Earnings Calendar for a full list of expected earnings releases. Home Depot, Inc. (HD)is repo...
Oculis Holding GAAP EPS of CHF -0.32
* Oculis Holding press release [https://seekingalpha.com/pr/20301359-oculis-reports-q3-2025-financial-results-and-provides-company-update] (OCS [https://seekingalpha.com/symbol/OCS]): Q3 GAAP EPS of...
Oculis birtir uppgjör fyrir þriðja ársfjórðung 2025 og kynnir áfanga í rekstri félagsins
ZUG, Sviss, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Oculis hraðar þróunaráætlun sinni í kjölfar árangursríks fundar með Matvæla- og lyfjastofnun Bandaríkjanna (FDA), með PIONEER-rannsóknar�...
Oculis Reports Q3 2025 Financial Results and Provides Company Update
Oculis accelerates its portfolio development with Privosegtor moving into the PIONEER pivotal program in Acute Optic Neuritis (AON) andNon-arteritic Anterior Ischemic Optic Neuropathy (NAION) followin...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.